In addition, the mean percentage of IGF1 bioactivity over total IGF1 was 0.81% in the 15 subjects with active acromegaly indicating that the IGF1 KIRA assay provides information about the circulating IGF1 system that fundamentally differs from that obtained by IGF immunoassays. This evidence concerns the gene IGF1 and acromegaly.